Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT01212913
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 161 participants
- Sponsor
- Registry
-
NCT01212913
-
- Other papers using this trial's data
- Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01212913. Randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
- Acronym
- B to B
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- INSULIN GLARGINE
- Intervention (Drug)
- INSULIN GLULISINE
- Intervention (Drug)
- Insulin aspart
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01212913- Content hash
3342afb293ef575cc10f1afb0a9f186db032a310342a7cbc2daf73577b6b6b73